Myeloproliferative Neoplasms (MPN)

First-in-Class Drug Wins FDA Approval for Polycythemia Vera

The FDA has approved rusfertide (Mimrylo), a first-in-class hepcidin mimetic, for erythrocytosis in adults with polycythemia vera, a rare myeloproliferative neoplasm. The drug mimics hepcidin, the hormone regulating iron availability, with the aim of controlling haematocrit and reducing the need for…